Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
Recruiting
N/A
Interventional Study
Breast Cancer With Low to Intermediate HER2 Expression
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 79
- Sex
- Female
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 20 (estimated)
- Sponsor
- University of Rochester · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female sex, age 18-79 years.
* Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
* Baseline LVEF ≥ 55 % by 2-D echocardiography.
* Ability to provide informed consent.
Exclusion Criteria:
* Prior HF, myocardial infarction, or cardiomyopat…
Contacts